New Albany - Rita Elizabeth Naville, 92, passed away Friday April 2, 2021 at the Baptist Health Floyd Hospital. She was the former Rita Poff, born in New Albany to the late William and Elizabeth ...

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.

While Japan’s Eisai had set the goal to reach 10,000 patients with Leqembi by the end of its 2024 fiscal year, which wraps up in March, only 2,000 patients in the U.S. were receiving the amyloid ...

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for ...

The subject experienced swelling and bleeding in the brain, an Eisai spokeswoman said. It wasn’t clear if the death was directly caused by the drug lecanemab in a clinical trial.

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month.

Eisai made history last year as Biogen’s partner on Aduhelm, the first approved Alzheimer’s treatment in decades. And yes, they know the launch could have gone better.

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Eisai, which markets major blockbuster-in-waiting Leqembi for Alzheimer’s disease, a form of dementia, is launching Theoria technologies in Japan next April to “accelerate the development of a ...